Trial Profile
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets Given Orally Once Daily for 12 Days to Young and Elderly Healthy Male and Female Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Study)(Part 1) and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 After Oral Administration in the Morning Versus Oral Administration in the Evening in Young Healthy Male and Female Volunteers (Randomised, Two-sequence, Open, Two Period, Two-way Cross Over) (Part 2)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Iclepertin (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 30 May 2018 Results (n=96) safety, tolerability, and pharmacokinetics of multiple rising doses of BI 425809 tablets given orally once daily for 12 days to young and elderly healthy male and female volunteers, were published in the Clinical Drug Investigation.
- 19 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Nov 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.